Chemical Component Summary

FormulaC26 H29 N O2
Molecular Weight387.51
Isomeric SMILESCC\C(=C(/c1ccc(O)cc1)c1ccc(OCCN(C)C)cc1)c1ccccc1

Chemical Details

Formal Charge0
Atom Count58
Chiral Atom Count0
Chiral Atomsn/a
Bond Count60
Aromatic Bond Count18
Leaving Atomsn/a

Drug Info: DrugBank

DrugBank IDDB04468 Different stereochemistry
DescriptionAfimoxifene (4-Hydroxytamoxifen, trade name TamoGel) is a new estrogen inhibitor under investigation for a variety of estrogen-dependent conditions, including cyclic breast pain and gynecomastia. TamoGel is formulated using Enhanced Hydroalcoholic Gel (EHG) Technology. This technology enables percutaneous delivery of drugs that cannot be delivered orally. It is being developed by Ascent Therapeutics.
  • 4-Hydroxytamoxifen
  • 4-monohydroxytamoxifen
  • 4-OHT
Brand NamesTamogel
Affected OrganismHumans and other mammals
IndicationFor the potential treatment of menstrual-cycle related mastalgia, fibrocystic breast disease, breast disease, gynecomastia and Keloid scarring.
Mechanism of actionAfimoxifene binds to estrogen receptors (ER), inducing a conformational change in the receptor. This results in a blockage or change in the expression of estrogen dependent genes.
  • Androstanes
  • Androstenes
  • Androstenols
  • Antineoplastic Agents
  • Benzene Derivatives
CAS number68392-35-8
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682